{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:21:24Z","timestamp":1770283284634,"version":"3.49.0"},"reference-count":26,"publisher":"Portland Press Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":192,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is a hematological malignancy of plasma cells that produce a monoclonal immunoglobulin protein. Despite significant advances in the treatment of MM, challenges such as resistance to therapy remain. Currently, inhibition of histone deacetylases (HDACs) is emerging as a potential method for treating cancers. Numerous HDAC inhibitors are being studied for the use in monotherapy or in conjunction with other agents for MM. In the present study, we investigated the anti-myeloma effect of Nexturastat A (NexA), a novel selective HDAC6 inhibitor. We found that NexA impaired MM cells viability in a dose- and time-dependent manner. NexA also provoked a cell cycle arrest at the G1 phase in MM cells. Furthermore, NexA promoted apoptosis of MM cells via transcriptional activation of the p21 promoter, which may through its ability to up-regulate the H3Ac and H4Ac levels. Additionally, NexA could overcome bortezomib (BTZ) resistance in MM cells, and NexA in combination with BTZ had stronger efficacy. We also confirmed that NexA inhibited tumor growth in murine xenograft models of MM. These interesting findings provided the rationale for the future advancement of this novel HDAC6 inhibitor as a potential therapeutic anti-myeloma agent.<\/jats:p>","DOI":"10.1042\/bsr20181916","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T16:49:28Z","timestamp":1550594968000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma"],"prefix":"10.1042","volume":"39","author":[{"given":"Xiaoyang","family":"Sun","sequence":"first","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xie","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshen","family":"Sun","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hujun","family":"Li","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruosi","family":"Yao","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"key":"2021111619313951700_B1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"2021111619313951700_B2","doi-asserted-by":"publisher","first-page":"104546","DOI":"10.1155\/2013\/104546","article-title":"Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement","volume":"2013","author":"Tosi","year":"2013","journal-title":"Scientifica"},{"key":"2021111619313951700_B3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2021111619313951700_B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/2045-3701-4-45","article-title":"Epigenetic regulation in cancer progression","volume":"4","author":"Baxter","year":"2014","journal-title":"Cell Biosci."},{"key":"2021111619313951700_B5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.clml.2013.03.016","article-title":"Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy","volume":"13","author":"Kaufman","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2021111619313951700_B6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.leukres.2013.03.006","article-title":"Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma","volume":"37","author":"Richardson","year":"2013","journal-title":"Leukemia Res."},{"key":"2021111619313951700_B7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12185-016-2008-0","article-title":"Histone deacetylase inhibitors in multiple myeloma: from bench to bedside","volume":"104","author":"Harada","year":"2016","journal-title":"Int. J. Hematol."},{"key":"2021111619313951700_B8","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth","volume":"55","author":"Bergman","year":"2012","journal-title":"J. Med. Chem."},{"key":"2021111619313951700_B9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.molonc.2015.04.002","article-title":"Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation","volume":"9","author":"Woan","year":"2015","journal-title":"Mol. Oncol."},{"key":"2021111619313951700_B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","article-title":"Bortezomib resistance in multiple myeloma is associated with increased serine synthesis","volume":"5","author":"Zaal","year":"2017","journal-title":"Cancer Metab."},{"key":"2021111619313951700_B11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"2021111619313951700_B12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"2021111619313951700_B13","doi-asserted-by":"publisher","first-page":"20003","DOI":"10.1073\/pnas.1013754107","article-title":"Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents","volume":"107","author":"Namdar","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111619313951700_B14","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"2021111619313951700_B15","doi-asserted-by":"publisher","first-page":"e0173507","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor","volume":"12","author":"North","year":"2017","journal-title":"PLos One"},{"key":"2021111619313951700_B16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"(N-hydroxycarbonylbenylamino) quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J. Med. Chem."},{"key":"2021111619313951700_B17","first-page":"1593","article-title":"The cdk2 kinase is required for the G1-to-S transition in mammalian cells","volume":"8","author":"Tsai","year":"1993","journal-title":"Oncogene"},{"key":"2021111619313951700_B18","doi-asserted-by":"publisher","first-page":"C1193","DOI":"10.1152\/ajpcell.1998.275.5.C1193","article-title":"Caco-2 intestinal cell differentiation is associated with, G1 arrest and suppression of CDK2 and CDK4","volume":"275","author":"Ding","year":"1998","journal-title":"Am. J. Physiol."},{"key":"2021111619313951700_B19","doi-asserted-by":"publisher","first-page":"e1281865","DOI":"10.1080\/23723556.2017.1281865","article-title":"Caspase-9 swings both ways in the apoptosome","volume":"4","author":"Wu","year":"2017","journal-title":"Mol. Cell. Oncol."},{"key":"2021111619313951700_B20","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.4161\/cc.9.12.11988","article-title":"Ubiquitylation and proteasomal degradation of the p21 (Cip1), p27 (Kip1) and p57 (Kip2) CDK inhibitors","volume":"9","author":"Lu","year":"2010","journal-title":"Cell Cycle"},{"key":"2021111619313951700_B21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1006\/excr.1999.4644","article-title":"p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells","volume":"253","author":"Kang","year":"1999","journal-title":"Exp. Cell Res."},{"key":"2021111619313951700_B22","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.3748\/wjg.v21.i42.12150","article-title":"Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy","volume":"21","author":"Ohkoshi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"2021111619313951700_B23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.biocel.2007.03.001","article-title":"Histone deacetylase inhibitors: signalling towards p21cip1\/waf1","volume":"39","author":"Ocker","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2021111619313951700_B24","doi-asserted-by":"publisher","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111619313951700_B25","doi-asserted-by":"publisher","first-page":"e18569","DOI":"10.1200\/jco.2011.29.15_suppl.e18569","article-title":"The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM)","volume":"29","author":"Santo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"2021111619313951700_B26","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl D","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181916\/841842\/bsr-2018-1916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181916\/841842\/bsr-2018-1916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:22:31Z","timestamp":1637094151000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/3\/BSR20181916\/111018\/The-selective-HDAC6-inhibitor-Nexturastat-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20181916","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3]]},"article-number":"BSR20181916"}}